Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 February 2015Website:
http://www.rocketpharma.comNext earnings report:
26 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 19 Nov 2024 22:33:16 GMTDividend
Analysts recommendations
Institutional Ownership
RCKT Latest News
On Monday, Rocket Pharmaceuticals, Inc. RCKT presented long-term safety and efficacy results from the Phase 1 study of RP-A501 in male patients with Danon disease.
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.
Enrollment completed for pivotal single-arm phase 2 study, using RP-A501 for the treatment of male patients with Danon disease. Promise for RP-A501 program lies with the potential to receive FDA Accelerated Approval for the treatment of male patients with Danon disease. The Danon disease treatment market is expected to reach $2.82 billion by 2030.
The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Rocket Pharmaceuticals (RCKT) shares declined in intraday trading Friday after the biopharmaceutical firm announced that the Food and Drug Administration (FDA) wants more data about its gene therapy to treat a rare immune disorder in children before granting approval.
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
Rocket Pharmaceuticals (RCKT) could experience an increase in value due to increasing confidence in its potential earnings, as evidenced by its upgrade to a Zacks Rank #2 (Buy).
Rocket Pharmaceuticals, Inc. has potential FDA approvals for its gene therapies on the horizon. The company focuses on developing gene therapies for rare diseases, targeting a market that is expected to triple in value by the end of the decade. Rocket's pipeline includes promising therapies for severe leukocyte adhesion deficiency-I, Danon Disease, and Fanconi Anemia, among others.
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
- 1(current)
What type of business is Rocket Pharmaceuticals?
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
What sector is Rocket Pharmaceuticals in?
Rocket Pharmaceuticals is in the Healthcare sector
What industry is Rocket Pharmaceuticals in?
Rocket Pharmaceuticals is in the Biotechnology industry
What country is Rocket Pharmaceuticals from?
Rocket Pharmaceuticals is headquartered in United States
When did Rocket Pharmaceuticals go public?
Rocket Pharmaceuticals initial public offering (IPO) was on 18 February 2015
What is Rocket Pharmaceuticals website?
https://www.rocketpharma.com
Is Rocket Pharmaceuticals in the S&P 500?
No, Rocket Pharmaceuticals is not included in the S&P 500 index
Is Rocket Pharmaceuticals in the NASDAQ 100?
No, Rocket Pharmaceuticals is not included in the NASDAQ 100 index
Is Rocket Pharmaceuticals in the Dow Jones?
No, Rocket Pharmaceuticals is not included in the Dow Jones index
When was Rocket Pharmaceuticals the previous earnings report?
No data
When does Rocket Pharmaceuticals earnings report?
The next expected earnings date for Rocket Pharmaceuticals is 26 February 2025